Information Provided By:
Fly News Breaks for January 15, 2020
ALXN
Jan 15, 2020 | 07:38 EDT
Raymond James analyst Steven Seedhouse raised his price target for Alexion Pharmaceuticals to $162 and maintained an Outperform rating following the JPM20 conference. In a research note to investors, Seedhouse says Alexion's CEO reiterated that no value would be added if Alexion proactively seeks to sell itself and the company refused to discuss potential interest rumors because :we have better things to do than just address rumors," and that management clarified that after consulting KOLs and regulators and due to the rapidly progressing nature of the disease, the Ultomiris for ALS program was converted from proof of concept to potentially registrational Phase 3 study starting in Q1.
News For ALXN From the Last 2 Days
There are no results for your query ALXN